Mumbai, May 25 -- Profit before tax (PBT) increased 30.63% YoY to Rs 85.22 crore in Q4 FY26.

Operating EBITDA dropped 8% to Rs 112.1 crore in Q4 FY26 from Rs 121.9 crore posted in Q4 FY25. EBITDA margin contracted to 667 bps to 21% in Q4 FY26 as against 27.6% in Q4 FY25.

Revenue from infusion therapy segment rose 1.9% YoY to Rs 256.1 crore while revenue from renal segment climbed 21.3% YoY to Rs 56.2 crore and revenue from others segment stood at Rs 222.1 crore, up 55.2% YoY.

On full year basis, the company's consolidated net profit fell 4.85% to Rs 322.13 crore on 12.3% increase in revenue from operations to Rs 1,875.25 crore in FY26 over FY25.

Meanwhile, the company's board recommended a dividend of Rs 3.5 per equity shares of Rs 5 ...